Made possible with a $4 million grant from the Brazilian Ministry of Health, CHOP cell therapy specialists will offer their expertise and resources to oversee this initiative.

CHOP has treated its 500th patient with CAR T-cell immunotherapy, a “living drug” that harnesses the power of a patient’s own immune system to fight cancer.

Two researchers from Children’s Hospital of Philadelphia (CHOP) were recently selected by the health and science news outlet STAT as 2022 Wunderkinds, an award that celebrates the next generation of scientific superstars who are making significant contributions to biomedical research.

A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.

Researchers from Children’s Hospital of Philadelphia (CHOP) have found that economically disadvantaged children treated with CAR T-cell therapy for relapsed/refractory acute lymphoblastic leukemia (ALL) fair just as well as children from more socioeconomically advantaged backgrounds.

CHOP researchers have identified a protein on the surface of multiple pediatric brain tumors that they can target using immunotherapy in preclinical models.

New data on show CAR T-cell therapy leads to durable remission and long-term survival in children and young adults with relapsed or refractory B-ALL.

A group of researchers that includes CHOP presented new data on CRISPR-edited gene therapy for blood disorders at an international meeting.

International collaboration aims to ensure more equitable access to transformative personalized cancer therapy.

CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.